Alexza Pharmaceuticals (ALXA) Getting Somewhat Negative News Coverage, Study Finds

News stories about Alexza Pharmaceuticals (NASDAQ:ALXA) have trended somewhat negative this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Alexza Pharmaceuticals earned a daily sentiment score of -0.03 on Accern’s scale. Accern also assigned news headlines about the healthcare company an impact score of 44.6829956520474 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Alexza Pharmaceuticals (ALXA) remained flat at $0.94 during mid-day trading on Wednesday. Alexza Pharmaceuticals has a 12 month low of $0.43 and a 12 month high of $1.03. The company’s 50-day moving average is $0.94 and its 200 day moving average is $0.94.

COPYRIGHT VIOLATION WARNING: “Alexza Pharmaceuticals (ALXA) Getting Somewhat Negative News Coverage, Study Finds” was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US and international copyright and trademark laws. The original version of this piece of content can be read at https://ledgergazette.com/2017/10/18/alexza-pharmaceuticals-alxa-given-daily-media-impact-score-of-0-03.html.

About Alexza Pharmaceuticals

Alexza Pharmaceuticals, Inc is a pharmaceutical company focused on the research, development and commercialization of products for the acute treatment of central nervous system conditions. The Company’s product candidates are based on the Staccato system technology. Its product candidates in development include AZ-002, which contains alprazolam as an active pharmaceutical ingredient (API) is developed for the management of patients with acute repetitive seizures, and AZ-007, which contains zaleplon as API is developed for the treatment of insomnia in patients who have difficulty falling asleep, including those patients with middle of the night awakening having difficulty falling back asleep.

Insider Buying and Selling by Quarter for Alexza Pharmaceuticals (NASDAQ:ALXA)

Receive News & Ratings for Alexza Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexza Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply